Population
Adults hospitalized with COVID-19 admitted to an intensive care unit (n= 176).
Intervention
Enoxaparin intermediate dose (n= 88).
Comparison
Enoxaparin standard dose (n= 88).
Outcome
In the intention-to-treat population, all-cause mortality at 30 days was 15% for intermediate dose enoxaparin and 21% for standard prophylactic dose enoxaparin. Unadjusted Cox proportional hazards modelling demonstrated no significant difference in mortality between intermediate and standard dose enoxaparin. Arterial or venous thrombosis occurred in 13% of patients assigned to intermediate dose enoxaparin and 9% of patients assigned to standard dose enoxaparin. Major bleeding occurred in 2% of patients in each arm.